Pyran is an oxygen-containing heterocyclic moiety, which exhibits an array of pharmacological properties.
Introduction
The expression "tumour" induces fear, particularly when one considers recent statistics of cancer cases worldwide. 1 Another cause for concern is the mammoth task that physicians must carry out in order to attempt to save patients' lives. A tumour is depicted by the uncontrolled development and spread of abnormal cells. While normal body cells grow, divide and die in an orderly fashion, cancer cells do not follow this norm. They rather continue to grow and divide in a disorderly fashion. The weapons used for this ght generally include specialised surgical operations, radiation therapy and chemotherapy.
Despite continued research efforts towards the development of anticancer (chemotherapeutic) drugs, cancer remains a primary cause of death. It is estimated that the number of cancer cases may reach up to 15 million at the end of 2020. [2] [3] [4] [5] [6] According to the World Health Organization (WHO), more than 80% of the world's population relies on traditional medicines for their essential health care needs. 7, 8 Plants have a long history of their utilization in the treatment of tumors and it is estimated that more than 60% of presently utilised anticancer agents are obtained from nature. 8 Heterocyclics represent the most abundant compound classes present among known drugs. Typically, the former need to be decorated with suitable Harmanpreet Singh studied pharmacy at the Punjab Technical University between 2006 and 2010. His post graduate work was within the eld of pharmaceutics (ISF college of Pharmacy), where he worked on the transmucosal delivery of docetaxel using nanober as a carrier system for the treatment of buccal cancer. He started his Ph.D. in 2014 at the Guru Nanak Dev University, Amritsar, India, where he is currently working on the development of different carrier system for increasing the bioavailability, shelf life and effective delivery of the docosahexanoic acid (DHA).
Girish Kumar Gupta graduated in pharmacy in 2006 from Guru Jambheswar University of Science and Technology, Hisar, India. In 2009 he obtained his Master's degree in pharmaceutical chemistry from the University Institute of Pharmaceutical Sciences, Kurukshetra University, Kurukshetra, Haryana, India. Currently working as Assistant Professor in M. M. College of Pharmacy, Maharishi Markandeshwar University, Mullana, Ambala, India, he has more than 8 years of research experience in pharmaceutical eld including academic and industrial research and teaching. He has over 60 publications in the eld of heterocyclic chemistry in peer reviewed high impact journals. He is also a member of many pharmaceutical associations and societies. He is also an editorial board member, editor, guest editor and reviewer of many reputed international and national journals. His area of research encompasses drug design, molecular modelling, green synthesis related to nitrogen containing heterocycles. substituents in order to obtain their appropriate biological effects. 9 Tremendous progress has been made in the war against cancer, with the development of many novel chemotherapeutic agents. However, due to toxicity and drug-resistance problems encountered with many currently available treatments, it remains a great challenge to discover and develop more effective drugs to treat cancer. We present the structure-activity relationships and their mechanistic insights established during the pharmacological evaluation of selected potent pyrans. The structures of the designed and synthesised molecules discussed in this compilation clearly highlight the interesting and promising anticancer proles of the compounds. An overview of selected molecular modeling studies has also been incorporated, with the aim of providing insight into the possible binding sites. This classication of the pyrans discussed in this study is based on one of the core functionalities of their chemical architecture. The classication is as follows:
Benzopyrans and fused pyran-based anticancer scaffolds. Flavones and fused avone-based anticancer scaffolds.
Coumarins and fused coumarin-based anticancer scaffolds.
Xanthones and xanthene-based anticancer scaffolds. Other scaffolds. A summary of the most potent compounds have been presented in the ESI (Table S1 †) .
Benzopyrans and fused pyranbased anticancer scaffolds
The pyran ring is the core unit of benzopyran, chromone, a-vanoids, coumarin, xanthones, and naphthoquinones, which exhibit diverse pharmacological activities. Pyran heterocycles are both prevalent across compounds classied as of 'natural origin' and 'man-made'. Numerous naturally occurring compounds containing pyrans and benzopyrans, show fascinating therapeutic activities. These have spurred considerable awareness of the synthetic arena based on their structure, reactivity, synthesis and biological properties. The classication of pyran heterocyclic compounds depends on the presence of the 2H or 4H pyran scaffold (Fig. 1) . Thus, the benzo derivative of 2H-pyran is named 2H-1-benzopyran (commonly 2H-chromene) and the benzo analogue of 4H-pyran is called 4H-1-benzopyran (commonly 4H-chromene).
10 Interrelated naphthyl derivatives are exemplied by 2H-naphtho[1,2,b]pyran and xanthenes. Ketones obtained from pyrans are called pyranones (likewise regularly pyrones), the parent molecules being pyran-2-one and pyran-4-one.
11-13 Paltry names are utilised for the related benzo analogues; coumarin, dihydrocoumarin, chromone, xanthone, and chromanone or chroman-4-one.
It is well established that small heterocyclic molecules are predominant building blocks for biologically active compounds, 14, 15 while an increasing number of structural frameworks have been described as privileged structures.
16
Pyran skeletons are important structural units found widely in natural products, e.g. sugars, coumarins, 17 avonoids, 18 anthraquinones, 19 etc. Examples include avonoid-based pyran derivatives (Fig. 2) , including epicalyxins F and G along with calyxins F, G, L and I (Fig. 2) , isolated from the seeds of Alpinia blepharocalyx. Epicalyxin F is the most potent member of this class, as an anticancer agent against human HT-1080 brosar-coma and murine 26-L5 carcinoma.
20
The bioactive metabolite, b-lapachone (20, Fig. 3 ), is a typical example of a pyran derivative, which generally shows diverse biological activities (e.g. anticancer, antibacterial and anti-inammatory activities), making it important for drug development. Zanamivir (22, Fig. 3 ), for example, was approved for prevention of inuenza A and B. Moreover, zanamivir was the rst commercially developed neuraminidase inhibitor. This drug is currently marketed by GlaxoSmithKline under the trade name of "Relenza". Laninamivir octanoate is a prodrug of laninamivir (23, Fig. 3 ), which is structurally similar to zanamivir and is administered orally. 21, 22 Pyran-based drugs, which are commercially available and/or are in preclinical/clinical trials have been shown in Fig. 3 . A literature survey has shown the abundance of commercially available therapeutic agents containing the pyran unit. Benzopyrans and fused pyran-based are an important class of structural motif for many natural and synthetic compounds, possessing high activity proles, due to their wide range of biological activities, including anticancer properties.
23-25
Madda et al. synthesised new chromeno-annulated cisfused pyrano [3,4-c] benzopyran and naphtho pyran analogues, and tested these compounds against different human cancer cell lines. It was shown that compounds 27 and 28 (Fig. 4) inhibitors. Substitution of the thiophene for the phenyl core in compound 30 resulted in compound 31, which showed a comparative or better PI3K and mTOR enzymatic inhibition prole than compound 30 (Fig. 5) . The former also showed a marginally better aqueous solubility, cell porosity, and better activity when tested in a PC3 cell expansion, while downregulating the PI3K pathway as shown by restraining pAKT-S473 levels.
27
The 4H-pyrano- [2,3-b] naphthoquinone scaffold is known to be a mimetic of an assorted assembly of naturally occurring pyranonaphthoquinones and their engineered analogues, with promising anticancer potentials.
28 Natural products within this class include rhinacanthin O (34, screened a synthesised library of molecules, exhibiting low micromolar antiproliferative activity and initiated apoptosis in human cancerous cells, towards a set of malignant cells.
34
Selected analogues exhibited promising activities against cancer cell lines impervious to professional apoptotic stimuli, thus exhibiting their potential in treating tumors with grim anticipations. It was found that compound 36 and 37 showed antiproliferative effects better than those of a-lapachone, even though the latter was optional to the regioisomeric blapachone.
Naturally occurring (dihydro) pyranonaphthoquinones can be found in bacteria, fungi, and higher plants, pointing to their biochemical relevance in nature. Many of these pyranonaphthoquinone derivatives have indeed been found to possess diverse and pronounced biological activities, including antimicrobial, antiparasitic, antiviral and anticancer properties. (44) showed an IC 50 value of 1.5 mM against KB and 3.6 mM in Hep-G2 cell lines.
35
Natural products bearing the furanone-fused pyranonaphthoquinone skeleton, with the tricyclic pharmacophore ( Fig. 8 ) also play an important role in medicinal chemistry, e.g. kalafungin (45), medermycin (46) , griseusin (47) and granaticin (48) . Kalafungin, for example, has shown activity against L5178Y mouse leukemic cells, as well as against AKT kinase. 36 Meanwhile, medermycin was shown to possess several biological activities, including cytotoxicity against K562 human myeloid leukemia, P-388 murine leukemia and L5178Y murine lymphoblastoma cell lines. 37 Griseusin and granaticin also have proven antiprotozoal, antibacterial, and cytotoxic activities.
38-40
Based on these evidences, Jiang et al. synthesised several compounds bearing this quinone-pyran-lactone tricyclic pharmacophore and evaluated their anticancer properties against several cell lines, including squamous carcinoma KB cells, vincristine-resistant KB/VCR cells, human lung cancer A549 cells, and human leukemia HL60 cells. 41 The most promising compounds were the stereoisomers with the 3 Flavone-based scaffolds
The term "avonoid" refers to a huge class of plant secondary metabolites, which are biosynthesised from common chalcone precursors. 43 Flavonoids are members of a much bigger family of more than 5000 naturally occurring polyphenolics, present in several foods of plant origin, which are known to be a rich source of anticancer drugs. 44, 45 These compounds are oen characterised by the presence of a common phenylbenzopyrone linkage (C6-C3-C6) in their structures. Several avonoid subclasses exist, depending on the saturation level and opening of the central pyran ring, including; avones, isoavones, avonols, avanonols, avanols, avanones and pterocarpans. 45, 46 Flavonoids exhibit a broad range of biological activities, e.g. anti-mutagenic, antiproliferative and antioxidant activities. [47] [48] [49] The antioxidants are usually involved in cell signaling, cell cycle regulation, and angiogenesis.
50-53
Flavanones have been thought to be quite promising in the search for new lead compounds in the eld of cancer chemotherapy. About a decade ago, Hsiao et 55 The results of another study, published soon aerwards, explored the antiproliferative effects of synthetic avanone derivatives on human breast cancer cells by way of p53-mediated apoptosis and the induction of cell cycle arrest at the G1 phase. 56 Usman et al. had previously reported the cytotoxic activities of avanones isolated from the bark of Cryptocarya costata. 57 A study of eight avanones on colorectal carcinoma cells indicated that 2 0 -OH avanone showed the most potent cytotoxic effect on these cancer cells, and cell death Myricetin (60, Fig. 12) 
83 It was experimentally demonstrated that compound 62 affects the growth of human breast cells MDA-MB-231. Results from the telomerase inhibition assay also demonstrated that compound 62 acts against human bosom cells MDA-MB-231, with an IC 50 value of 0.91 mM. The docking simulation of compound 75, towards the target site, was performed to get the likely binding mode. The docking pose showed that the heterocyclic ring was profoundly embedded into the dynamic site, forming hydrophobic associations with build-ups of Phe568, Pro627, with four methoxy groups having hydrophobic collaborations with residues Phe568, Pro627, Lys902, Val904 and Pro929 (Fig. 12) . Fig. 13) , with an IC 50 value of 2.9 mM, was the most potent compound against MDA-MB-231 cells, being approximately 12 times more potent, when compared with the reference drug (etoposide). It has been demonstrated that the modulation of the avanone structure could increase antitumor activity. Thus, chlorine substitution on the chromanone ring and on the C-2 attached phenyl ring was used for structural modication and modulation of the basic pharmacophore of avanones. Among the synthesised compounds (Fig. 13) 67 Topoisomerases are known to play essential roles in maintaining DNA topology during the processes of DNA replication, transcription and recombination. Thus, topoisomerase inhibitors are cytotoxic agents that bind to free topoisomerase and prevent the formation of a covalent enzyme-DNA complex, and are thereby referred to as topoisomerase antagonists or "topoisomerase poisons". A number of avonoids and other polyphenolic compounds are known to inhibit and poison mammalian topoisomerase I and II. These include quercetin, acacetin, apigenin, kaempferol, morin and luteolin. 45 The structural features of avonoids essential for the inhibition of topoisomerase have been described (Fig. 14) . 45 
Coumarin-based scaffolds
Coumarins and pyrans form an exceptional class of oxygencontaining heterocyclic compounds, which play a key role in medicinal chemistry, due to their structural diversity and pharmaceutical properties. 68 Coumarins play a special role in nature.
69,70
Coumarins scaffolds are present in natural phytoconstituents, exhibiting diverse biological activities, including anticancer properties through diverse mechanisms, [71] [72] [73] thus making it a privileged structure. These abilities have been explored in detail. 74 Coumarin scaffolds have also been explored through the formation of diverse hybrids, with promising biological activities (Fig. 15) .
75-79
Among the coumarin hybrids from natural sources are pyranocoumarin derivatives, having several structural arrangements between the coumarin and the pyran rings. The few important pyranocoumarins include xanthyletin (74) (predominantly isolated from Zanthoxylum americanum), khellactone (73) (isolated from Ligusticum elatum), arisugacins (75) , and pyripyropenes (76) (Fig. 16) . 80 Kumar et al. designed and synthesised 2,4-diarylpyrano[3,2-c]chromen-5(4H)-ones. 81 The design strategy involved the fusion of coumarin and chalcone, employing pyran as a linker. Among the obtained derivatives, compound 77 ( Fig. 17) revealed momentous effects in HCT 116 cell lines, with IC 50 values of 1.4 and 4.3 mM towards "MiaPaCa-2" cell lines. This compound was shown to initiate apoptosis as revealed by Hoechst 33258 staining, phase contrast microscopy, and mitochondrial membrane potential (MMP) loss. The cell phase division study indicated that the apoptotic population amplied from 10.22% in the control to 57.19% in a sample treated with compound 77 at a concentration of 20 mM. 81 Hussain et al. further conducted a novel synthesis of coumarin derivatives as potent anti-breast cancer agents against ER +ve and ER Àve cell lines. 82 Compound 85 was found to be ER-a selective and most dynamic from all synthesised molecules, exhibiting prospective antiproliferative activity. The docking simulation showed that compound 85 could favorably t well in the receptor cavity of ER-a, following the binding pattern similar to the standard drug. The coumarin nucleus and the p-methoxyphenyl group at the third position formed a hydrophobic interaction with the residues Glu353, Arg394, Phe404 and Leu349. The aroyl substituent at the fourth position, having the amino alkoxy chain, anchored the piperidine ring by forming hydrophobic contacts with Trp383, Asp351, Leu354, Leu536 and Thr347. The methoxy group of coumarin at the seventh position interacted with Glu353 and Arg394 (Fig. 18) . Compound 85 had a similar (but non-standard) binding pattern for ER-b binding, the coumarin pharmacophore forming hydrophobic interactions different from that observed in ER-a, i.e. interacting with Glu305, Arg346, Leu301, Leu339, and Leu343. At the third position, the 4-methoxyphenyl group forms a hydrophobic interaction with the amino residues Met421, Gly472, His575, Leu298, Phe356, Met340, and Ile373, which are essential features for ER-b binding.
82
Coumarin is a modication of the benzopyran-2-one by directed introduction of a heterocyclic substituent. In most cases, a heteroaryl substituent is introduced at position 3 or 4 of the coumarin ring. Thus, 3-and 4-heteroarylcoumarins are reported to exhibit signicant biological activities, including inhibiting the growth of several cancer types. 83 Prompted by this, Yana et al. reported the synthesis and anticancer evaluation of a series of novel 6-pyrazolinylcoumarins via NCI60-cell line assay. The outcome of the study revealed that compound 87 showed the highest level of anti-mitotic activity with a mean GI 50 value of 10.20 mM and a sensitivity prole toward the Leukemia cell lines CCRF-CEM and MOLT-4 (GI 50 values 1.88 mM and 1.92 mM), respectively, as represented in Fig. 19 . The SAR study indicated that the antitumor activity of the synthesised compounds depends on substituent at third and fourth positions of the coumarin core. Moreover, it was found that compounds bearing the 3-methoxy-4 hydroxyphenyl and the 4-hydroxyphenyl substituents at position 5 of the pyrazoline fragment were more active than the other analogues.
84
Another study was carried out on the design and synthesis of coumarin derivatives with improved anticancer activity. Among them, oligomerization (di/tri) of coumarin is one of the effective ways. 85, 86 The derived dimeric natural product was shown to be more effective than the monomeric species (with IC 50 $70 mmol L
À1
). 87, 88 With this inspiration, the concept of molecular oligomerization led to the discovery of two novel series of dimeric derivatives of triphenylethylene-coumarin hybrids. 89, 90 The dimeric compounds had potent anti-tumor activities, possibly by acting on DNA via the intercalative mode, and higher than their corresponding monomeric compounds, 91, 92 respectively. The positive results inspired interests to explore the trimeric variants of the triphenylethylene-coumarin hybrid in an effort to produce more efficient antitumour agents. Zhang et al. further discovered new trimers of triphenylethylene-coumarin hybrids, containing two amino side chains. The trimeric compound 88 (Fig. 20) exhibited signicant antiproliferative activity against three cancer cells at IC 50 of nearly 10 mmol L À1 .
The outcome of the DNA photocleavage studies revealed that compound 88 had signicant interaction with Ct-DNA by the intercalative mode. Overall, the presence of extended linker and piperidinyl substitutions on the side chains were found to be favourable for DNA binding and the antitumour activity. 93 
Xanthones and xanthene-based scaffolds
Xanthones are an outstanding class of oxygenated tricyclic compounds, which display different fascinating pharmacological properties, relying on the nature and types of substitutions. [94] [95] [96] Recently, xanthones have been valued as having an effective pharmacophore in the eld of medicinal chemistry world. 97 Prior to this, xanthones were shown to be present in bug sprays, larvicides and ovicides.
98 Shortly aerward, several experimental studies established that xanthone analogues could stop the growth of tumor cells and could also possess antioxidant and anti-inammatory properties. 99 Xanthones are mainly found in plants of the Bonnetiaceae and Clusiaceae, in addition to the Podostemaceae, Guttiferae and Gentianaceae.
100
Many naturally-occurring and man-made xanthene derivatives have been reported to exhibit antitumor activities, [101] [102] [103] [104] among others. In the recent past, there has been a renewed interest in the synthesis of this class of compounds as the number of its applications have increased, both in the eld of medicinal chemistry and material science. Particularly, xanthones (9H-xanthen-9-ones) are well explored heterocyclic derivatives with the dibenzo-g-pyrone skeleton.
105-108 Some xanthone-containing plant extracts are directly used in traditional medicines. Analogous thioxanthone derivatives are also present in anticancer drugs.
109-113 Moreover, there are some marketed formulations having xanthone derivatives (89-97, Fig. 21 ) as one of their active ingredients. Lee et al. isolated three coumarin derivatives, theraphins (98) (99) (100) (101) are recognised xanthones such as 2-hydroxyxanthone, 1,7-dihydroxyxanthone and 5-hydroxy-1-methoxyxanthone (Fig. 22) , from the bark of Kayea assamica (Clusiaceae).
114
These were analysed for their cytotoxic activities, based on a panel of human cancer cell lines. Among these compounds, 99-101 displayed cytotoxic action against Col-205, KB, and LNCaP cell lines with IC 50 values ranging from 3.5 to 13.1 mM. Meanwhile, the coumarin subsidiaries demonstrated modest effects, with IC 50 values in the range 9.7-11.1 mM against the D6 clone, and IC 50 values in the range 5.1-10.4 mM against the W2 clone. The result of the study demonstrated that the 7-hydroxycoumarins had an inhibitory impact on human malignant cell lines. 115 These analogues were screened for their cytotoxic effects in NCI-H187 (human lung cancer) cell line. Among these, compounds 90, 103 and 104 showed cytotoxic activities with IC 50 values ranging from 0.65 to 5.2 mg mL À1 . 111 Chantarasriwong et al. also established the series of caged Garcinia xanthones and evaluated them for their anticancer activity using cell proliferation and apoptosis assays against human colon and leukemic HCT-116 and HL-60 cell lines respectively. Compound 106 proved to be the most active compound against colon cancer cells, with an IC 50 value of 0.2 mM against HCT-116, while compound 107 was the most active against HL-60 (Leukemia), having an IC 50 value 0.4 mM, Fig. 23 .
116
In a similar study, Matsumoto et al. conrmed that all xanthones obtained from Garcinia mangostana (Fig. 24 ) demonstrated a noteworthy anticancer activity. 117 However, a, b and g-mangostins (90) (91) (92) were particularly active at 10 mM. The most active compound at this concentration was a-mangostin. The anticancer effect of a-mangostin was also shown in other leukemia cell lines: K562, NB4 and U937. Cell development of all these leukemia cell lines was hindered by a-mangostin at 5-10 mM. 117 Chiang et al. reported that the heated water concentrate of mangostin-organic product pericarp showed an intense antileukemic activity, with IC 50 values of 61 
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and 159 mg mL À1 against K562 and Raji cells, respectively.
118
Balunas et al. have also screened a, b and g-mangostins by using a non-cell, chemical based the microsomal aromatase hindrance assay with an IC 50 value 4.97 mM against SK-BR-3 breast cancer cell lines. 119 Recently, Jung et al. determined the antitumor properties of these compounds in pre-neoplastic injuries induced with 7,12-dimethylbenz[a]anthracene (DMBA) in a mouse mammary organ development. It was observed that a-mangostin restrained DMBA-induced preneoplastic sores with an IC 50 of 2.44 mM. 120 Suksamrarn et al. separated distinctive xanthones from mangosteen fruit pericarp and tested them for antineoplastic activity against three diverse human malignant cells, e.g. mouth carcinoma (KB), breast cancer (BC-1) and small cell lung cancer (NCI-H187), with IC 50 values of 2.8, 3.53 and 3.72 mg mL À1 , respectively. 121 Nonetheless, a-mangostin (90) showed the most pronounced effect on BC-1 cells, with an IC 50 value of 0.92 mg mL À1 . It was found that an action of a-mangostin was further noteworthy than the standard medication ellipticine (IC 50 ¼ 1.46 mg mL À1 ).
121
Chen et al. veried that a-and g-mangostins appreciably subdued lipopolysaccharide-stimulated NOc production and cytotoxic effects when applied to RAW 264 cells. 122 The quantity of NOc fabrication at 3 to 25 mM was continuously calculated, and the IC 50 values were found to be 12.4 and 10.1 mM for a-and 123 Nutritional administration of a-mangostin altogether hindered the acceptance and improvement of unusual grave foci in an articially instigated rodent model of colon carcinogenesis. The development of COLO 205 xenogras was totally stied when mice were infused intraperitoneally with 3 mg of a mangostin extract containing a-and g-mangostin. In addition, minor doses of the extract were decreased the tumor volume. Atomic component kappa-B (NF-kB) action was also diminished by 30%. The balb/c mice bearing colon tumor NL-17 xenogras indicated 50-70% lessening in tumor size when intraperitoneal treated with a concentrate from mangosteen pericarp containing 25% a-mangostin.
123-126
Cao et al. isolated two new cytotoxic xanthones; termicalcicolanone A (108) and termicalcicolanone B (109, Fig. 25 ) from the ethanolic extract of the Madagascan plant Terminalia calcicola.
127
These compounds were evaluated for their antiproliferative activity in the A2780 human ovarian cancer cell line assay and had IC 50 values of 40.6 and 8.1 mM, respectively. 127 Han et al. isolated three new prenylated xanthones, along with ten known compounds, from the stem bark of Garcinia lancilimba.
128 These analogues were tested for their apoptotic effects against HeLa-C3 cells, which produce a biosensor procient in detecting caspase-3 activation and it had been found out that 7,9,12-trihydroxy-2,2-dimethylpyrano [3,2-b]xanthen-6(2H)-one (110, Fig. 25 ), also arresting cell mitosis by interfering with microtubule formation and then induce apoptotic cell death. 128 Tao et al. isolated new xanthones, a pair of new natural products and known related compounds (Fig. 25 ) from the resin of Garcinia hanburyi.
129 These compounds were evaluated for their cytotoxicity against HeLa cervical carcinoma cells, with adriamycin as the positive control and all except compound 111 (IC 50 ¼ 111 mM) was found to display most potent cytotoxicity (Fig. 25) .
129
Garcinia hanburyi, resin (named gamboge) is originally used as pigment and folk medicine. In recent years, a special group of xanthones, caged Garcinia xanthones, which have been identied as bioactive compounds with potent biological properties, e.g. antitumor, anti-HIV-1, antibacterial, and anti-inammatory activities. The compounds occur naturally in the resin, fruit, and other parts of the plant. Han et al. reported 40 different xanthones from G. hanburyi. Furthermore, multiple mechanisms of cytotoxic activity have been reported, such as cell cycle 131, 132 The modied xanthones were found to exhibit the most potent antitumor activities by inducing apoptosis in HepG2 cell lines in a dose-dependent manner. 133 It was found that the efficiency of cell growth inhibition increased dramatically when the concentration of modied xanthones was increased. 136 The synthesised xanthenes (Fig. 28) were evaluated against a group of six human tumor lines such as SW-620, 502713 and Colo-205 (colon), SKNSH (CNS), A-549 (lung) and PC-3 (prostate), using 
respectively.
137 Caxanthones A-E, with anticancer properties, which were identied from Codonopsis ovata.
139 While coxanthone B showed signicant inhibitory activity against SF-295 and MDAMB-435 (IC 50 values of 7.0 and 15.0 mM, respectively), coxanthone A showed cytotoxicity against the A549 cell line (IC 50 value of 22.5 mM). Meanwhile, the cytotoxic activity of 1-hydroxy-3,5-dimethoxyxanthone, swertiperenine and 1,7,8-trihydroxy-3-methoxyxanthone were shown to be with IC 50 values of 3.0, 5.0 and 21.0 mM against A549, MDAMB-435, and A549 cell lines, respectively.
138 Among synthesised xanthones with promising anticancer properties, Mulakayala et al. showed (124) and its analogues could be good starting points for anticancer drug discovery programs, as this compound and its analogues showed good antiproliferative properties in vitro against three cancer cell lines (with IC 50 values between 23 and 38 mM).
139
6 Other scaffolds
Mohareb and Schatz described 1,3,4-oxadiazine pyran derivatives with highly potent activities against breast adenocarcinoma (MCF-7), non-small cell lung cancer (NCI-H460) and CNS cancer (SF-268), some of which showed better inhibitory effect towards three cell lines than the standard drug doxorubicin, among which compounds 125 to 128 (Fig. 29) showed submicromolar activities. 140 Kumar et al. also designed and synthesised a number of chromeno [4,3-b] quinoxaline derivatives with activities against human metastatic breast cancer cells (MDA-MB 231) and human chronic myeloid leukemia cells (K562). 141 The most potent compounds (129 to 133, Fig. 30 ) inhibited the growth of the cancer cells up to about 50% at 1 mM.
Conclusions
The pyran scaffold has received much attention of researchers both from the pharmaceutical industries and academic organizations in the recent past. As evident from numerous cited papers, the pyran scaffold is the building block of various coumarins, xanthones and avonoids present in various natural plants. Numerous compounds containing pyran nucleus have displayed inhibitory activities with IC 50 values in the micromolar range. The overall conclusion is that pyran being one of the privileged heterocycles has shown a wide array of biological activities, particularly against cancer. There is abundant evidence that the utilization of diversely substituted pyran analogues has provided the platform for identication of new chemical entities which could be drug candidates with diverse biological properties. The in vitro, in vivo, and in silico experiments have shown pyrans to be molecules with potentially exploitable structures for the development of new cytotoxic and anticancer agents. Moreover, structures of designed and synthesised molecules discussed in this compilation clearly highlight the interesting and promising anticancer proles along with their structure-activity relationships. A discussion of the key interactions with the amino acid in selected binding sites, as demonstrated by molecular modeling studies, has also been provided. 
